Mobile version of drug safety reporting solution launched

Drug safety specialists, MyMeds&Me, have launched an enhanced, intuitive, mobile-web version of its safety reporting solution Reportum Public.

Coinciding with World Patient Safety Day (17 Sep), this solution enables patients and healthcare professionals to report adverse events directly to Marketing Authorisation Holders.

Importantly Reportum Public is optimised to work on any device, across multiple regions and languages, while providing high levels of scalability, security and data privacy through its GxP infrastructure.

Reportum Public is being rolled out to pharmaceutical partners and will provide patient and healthcare professionals with access to an integrated solution for direct data capture and digital automation of the overall process.

The goal is to provide the life sciences industry with much deeper and quicker access to the safety profiles of medicines.

The World Health Organisation (WHO) estimates 134 million adverse events occur each year, with medication errors costing health care systems approximately $42 billion annually.

Unveiled publicly on the first World Patient Safety Day, the enhanced mobile-web version of Reportum Public delivers rapid access to accurate, complete and standardised safety data for the earliest detection of safety or quality issues of medicines.

To date, close to half a million adverse events and product quality complaints have been processed through Reportum on behalf of pharmaceutical clients.

Dr Andrew Rut, CEO and Founder of MyMeds&Me, said: “World Patient Safety Day is an important reminder that patients and indeed consumers are at the centre of everything we do.

“While WHO estimates that there are 134 million adverse events annually across the globe, the number attributed to adverse drug reactions (ADRs) is likely to be around 15 million.  However, given under-reporting this is but a fraction of the true number of ADRs experienced by patients.

“With increasing accelerated approvals and an ever greater diversity of the target population, pharmacovigilance systems lack data on the adverse effects of medicines on individuals.

“Therefore we are proud to announce the secure mobile-web version of Reportum Public, to further enhance patients’ and healthcare professionals’ user experiences.

“Reportum Public enables data capture around drug safety to go even further, helping the pharmaceuticals industry to map the risk profile of its medicines and ultimately ensure the best outcome for patients.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...